10-QPeriod: Q2 FY2007

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2007

Filed August 9, 2007For Securities:ALNY

Summary

This 10-Q filing for Alnylam Pharmaceuticals, Inc. (ALNY) as of August 9, 2007, provides an update on the company's financial condition and results of operations for the second quarter and first half of 2007. As a clinical-stage biopharmaceutical company, Alnylam's financial performance is heavily influenced by its research and development activities, strategic partnerships, and progress in its pipeline. Investors should focus on the company's cash burn rate, the stage of development of its lead drug candidates, and any significant updates on its collaborations and potential future revenue streams. The report details the company's financial statements, management's discussion and analysis, and risk factors, all of which are critical for understanding the company's operational progress and financial health. Key areas of interest for investors include the company's liquidity position, its ability to fund ongoing R&D, and the potential commercial viability of its RNA interference (RNAi) therapeutics. While specific financial figures are not provided in the prompt, the structure of the filing indicates a detailed review of the balance sheet, income statement, and cash flows, along with management's commentary on the factors driving these results. Investors should pay close attention to the "Management's Discussion and Analysis" section for insights into the company's strategic direction, operational challenges, and future outlook.

Key Highlights

  • 1The filing contains unaudited condensed consolidated financial statements, including balance sheets, statements of operations, and cash flows for the periods ending June 30, 2007, and comparative periods in 2006.
  • 2Management's Discussion and Analysis (MD&A) section provides crucial insights into the company's financial condition, results of operations, and critical accounting policies.
  • 3Detailed information on research and development expenses is expected within the Statements of Operations, reflecting Alnylam's core business activities.
  • 4The filing includes disclosures regarding market risk and information on the company's internal controls and procedures.
  • 5Risk factors are detailed in Part II, offering potential investors a comprehensive understanding of the challenges and uncertainties associated with Alnylam's business and its RNAi therapeutic platform.
  • 6The report covers various segments of the financial information, from the balance sheet to disclosures about market risk, providing a holistic view of the company's financial standing.

Frequently Asked Questions

Based on the structure of the filing, Alnylam Pharmaceuticals is focused on developing RNA interference (RNAi) therapeutics. The financial statements and MD&A are expected to detail the expenses and progress related to these programs.

The Condensed Consolidated Balance Sheets as of June 30, 2007, and December 31, 2006, along with the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2007, and 2006, will provide key insights into Alnylam's liquidity, including its cash, cash equivalents, and working capital position.

The 'Risk Factors' section (Item 1A in Part II) is expected to detail the specific risks Alnylam faces. These likely include risks related to the development and regulatory approval of RNAi therapeutics, competition, intellectual property, reliance on partnerships, and the inherent uncertainties of biopharmaceutical development.

As a clinical-stage company, Alnylam's revenue generation primarily comes from collaborations and licensing agreements with larger pharmaceutical companies, potentially including upfront payments, milestone payments, and royalties. The Statements of Operations and MD&A would detail any such revenue recognized.